• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy.

作者信息

Belen-Apak F Burcu, Sarıalioğlu F

机构信息

Department of Paediatric Haemotology and Oncology, Faculty of Medicine, Baskent University, Sehit Temel Kuguluoglu Str. No:24, Bahcelievler, Ankara, Turkey.

出版信息

J Thromb Thrombolysis. 2020 Aug;50(2):278-280. doi: 10.1007/s11239-020-02129-0.

DOI:10.1007/s11239-020-02129-0
PMID:32372336
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7200048/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/799c/7200048/0ff3a0a1a821/11239_2020_2129_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/799c/7200048/0ff3a0a1a821/11239_2020_2129_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/799c/7200048/0ff3a0a1a821/11239_2020_2129_Fig1_HTML.jpg

相似文献

1
Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy.新型冠状病毒肺炎中的肺血管内凝血：可能的发病机制及抗凝/溶栓治疗建议
J Thromb Thrombolysis. 2020 Aug;50(2):278-280. doi: 10.1007/s11239-020-02129-0.
2
Coagulation abnormalities and thrombosis in patients with COVID-19.新型冠状病毒肺炎患者的凝血异常与血栓形成
Lancet Haematol. 2020 Jun;7(6):e438-e440. doi: 10.1016/S2352-3026(20)30145-9. Epub 2020 May 11.
3
COVID-19 coagulopathy: an evolving story.新冠病毒感染相关凝血功能障碍：一个不断演变的故事。
Lancet Haematol. 2020 Jun;7(6):e425. doi: 10.1016/S2352-3026(20)30151-4.
4
Impact of the COVID-19 pandemic on therapeutic choices in thrombosis-hemostasis.2019年冠状病毒病大流行对血栓形成-止血治疗选择的影响。
J Thromb Haemost. 2020 Jul;18(7):1794-1795. doi: 10.1111/jth.14845. Epub 2020 May 11.
5
Viral Coagulopathy in Patients With COVID-19: Treatment and Care.新型冠状病毒肺炎患者的凝血功能障碍：治疗与护理。
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620936776. doi: 10.1177/1076029620936776.
6
The Effect of Anticoagulation Use on Mortality in COVID-19 Infection.抗凝治疗对新冠病毒感染患者死亡率的影响。
Am J Cardiol. 2020 Nov 1;134:155-157. doi: 10.1016/j.amjcard.2020.08.005. Epub 2020 Aug 15.
7
COVID-19-Related Aortic Thrombosis: A Report of Four Cases.新型冠状病毒肺炎相关主动脉血栓形成：4例报告
Ann Vasc Surg. 2020 Aug;67:10-13. doi: 10.1016/j.avsg.2020.05.031. Epub 2020 May 29.
8
Anticoagulation in COVID-19: DDI Perspective.COVID-19中的抗凝治疗：药物相互作用视角
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620959457. doi: 10.1177/1076029620959457.
9
2020 - Year of COVID-19.2020年——新冠疫情之年。
J Thromb Haemost. 2020 Sep;18(9):2081. doi: 10.1111/jth.15041.
10
[Pulmonary embolism or pulmonary thrombosis in situ in severe pneumonic COVID-19 associated coagulopathy: does systemic thrombolysis have a role?].[重症肺炎型新型冠状病毒肺炎相关凝血病中的肺栓塞或原位肺血栓形成：全身溶栓治疗是否起作用？]
Medicina (B Aires). 2020;80(5):581-582.

引用本文的文献

1
The Mediating Role of Inflammation and Coagulation in the Association Between COVID-19 and 3-Month Outcome After Stroke During the Omicron Wave.炎症和凝血在奥密克戎毒株流行期间新冠病毒感染与中风后3个月预后关联中的中介作用
J Inflamm Res. 2024 Oct 10;17:7171-7182. doi: 10.2147/JIR.S465127. eCollection 2024.
2
Clinical characteristics and outcomes of venous thromboembolism in patients hospitalized for COVID-19: Systematic review and meta-analysis.因新冠肺炎住院患者静脉血栓栓塞症的临床特征及预后：系统评价与荟萃分析
Thromb Update. 2021;2:100037. doi: 10.1016/j.tru.2021.100037. Epub 2021 Mar 19.
3
Biopharmaceutical Assessment of Mesh Aerosolised Plasminogen, a Step towards ARDS Treatment.

本文引用的文献

1
Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans.非裔美国人 COVID-19 患者的肺部和心脏病理学：来自新奥尔良的尸检系列。
Lancet Respir Med. 2020 Jul;8(7):681-686. doi: 10.1016/S2213-2600(20)30243-5. Epub 2020 May 27.
2
Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection.关于：耐心等待抗白细胞介素6疗法治疗重症新型冠状病毒肺炎感染的结果。
Autoimmun Rev. 2020 Jul;19(7):102560. doi: 10.1016/j.autrev.2020.102560. Epub 2020 May 1.
3
Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?
雾化纤溶酶原网状物的生物制药评估：迈向急性呼吸窘迫综合征治疗的一步
Pharmaceutics. 2023 May 30;15(6):1618. doi: 10.3390/pharmaceutics15061618.
4
Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience.基于单中心经验的重症新型冠状病毒肺炎患者托珠单抗治疗临床反应预测指标的识别
J Clin Med. 2023 Mar 22;12(6):2429. doi: 10.3390/jcm12062429.
5
COVID-19: Mechanisms, risk factors, genetics, non-coding RNAs and neurologic impairments.新型冠状病毒肺炎：发病机制、风险因素、遗传学、非编码RNA与神经功能障碍
Noncoding RNA Res. 2023 Jun;8(2):240-254. doi: 10.1016/j.ncrna.2023.02.007. Epub 2023 Feb 23.
6
Coagulation Disorders in Sepsis and COVID-19-Two Sides of the Same Coin? A Review of Inflammation-Coagulation Crosstalk in Bacterial Sepsis and COVID-19.脓毒症和新冠肺炎中的凝血障碍——同一枚硬币的两面？细菌感染性脓毒症和新冠肺炎中炎症与凝血相互作用的综述
J Clin Med. 2023 Jan 11;12(2):601. doi: 10.3390/jcm12020601.
7
Promising Drug Fondaparinux for the Treatment of COVID-19: an In Silico Analysis of Low Molecular Weight Heparin, Direct Oral Anticoagulant, and Antiplatelet Drug Interactions with Host Protease Furin.福沙那韦治疗 COVID-19 的前景：低分子肝素、直接口服抗凝药和抗血小板药物与宿主蛋白酶弗林相互作用的计算机分析。
Cardiovasc Drugs Ther. 2024 Jun;38(3):425-432. doi: 10.1007/s10557-022-07406-z. Epub 2022 Nov 19.
8
Hemostatic system and COVID-19 crosstalk: A review of the available evidence.止血系统与新型冠状病毒肺炎的相互作用：现有证据综述
World J Methodol. 2022 Sep 20;12(5):331-349. doi: 10.5662/wjm.v12.i5.331.
9
Tetrandrine Treatment May Improve Clinical Outcome in Patients with COVID-19.汉防己甲素治疗可能改善 COVID-19 患者的临床结局。
Medicina (Kaunas). 2022 Sep 1;58(9):1194. doi: 10.3390/medicina58091194.
10
Coagulation Profile in COVID-19 Patients and its Relation to Disease Severity and Overall Survival: A Single-Center Study.新型冠状病毒肺炎患者凝血谱特征及其与疾病严重程度和总生存率的关系：一项单中心研究。
Br J Biomed Sci. 2022 Apr 8;79:10098. doi: 10.3389/bjbs.2022.10098. eCollection 2022.
组织型纤溶酶原激活剂作为难治性新型冠状病毒肺炎相关急性呼吸窘迫综合征的一种新型治疗方法，是否具有作用？
J Trauma Acute Care Surg. 2020 Jun;88(6):713-714. doi: 10.1097/TA.0000000000002694.
4
Plasminogen improves lung lesions and hypoxemia in patients with COVID-19.纤溶酶原可改善 COVID-19 患者的肺部病变和低氧血症。
QJM. 2020 Aug 1;113(8):539-545. doi: 10.1093/qjmed/hcaa121.
5
The versatile heparin in COVID-19.新冠疫情中用途广泛的肝素。
J Thromb Haemost. 2020 May;18(5):1020-1022. doi: 10.1111/jth.14821. Epub 2020 Apr 27.
6
Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.两例肺癌患者 2019 年新型冠状病毒（COVID-19）肺炎早期阶段的肺部病理学表现。
J Thorac Oncol. 2020 May;15(5):700-704. doi: 10.1016/j.jtho.2020.02.010. Epub 2020 Feb 28.
7
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.异常的凝血参数与新型冠状病毒肺炎患者的预后不良有关。
J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13.
8
Defibrotide: properties and clinical use of an old/new drug.地夫可特：一种老药/新药的特性和临床应用。
Vascul Pharmacol. 2013 Jul-Aug;59(1-2):1-10. doi: 10.1016/j.vph.2013.05.001. Epub 2013 May 14.